In a 2014 analysis of biotech boards and a reprise analysis in 2016, Bruce Booth worked with life science recruiter Catalyst Advisors on this board talent blog. They estimated the demand for talent at>600 biotech Board Director spots needing to be filled in the few years following October 2016.
This blog is written by Samantha Truex, Atlas EIR and CEO of a stealth-stage biotech, as part of the From The Trenches feature of LifeSciVC.
At the end of every year, we host both our Atlas Venture Annual Meeting for our fund investors (Limited Partners) and our Atlas Retreat for senior industry executives. As a kickoff for these two meetings, we typically open with a “Year In Review” to frame up some of the important themes facing biopharma. This year, for the first (and maybe only) time, we’ve decided to share a video recording of the Year In Review 2018 here at LifeSciVC, with voiceover accompanying the slides. Here it is:
View the talk.
Over the past six years, the biotech sector has experienced an incredible run of IPOs, reflecting the longest and largest “open window” for new offerings. Much has been written about post-IPO performance here and elsewhere, but there’s been little discussion about equity sales by executive teams following these IPOs.
Robert Jacks, co-founder and former chief financial officer of Symbiomix Therapeutics, has taken over the reins of Cambridge, Mass.-based Indalo Therapeutics and will help guide the company in the development of therapies for patients suffering from serious fibrotic diseases such as NASH and idiopathic pulmonary fibrosis (IPF).
Today I will continue my time-honored January tradition of an optimistic blog post providing some bold predictions for the year ahead.
This post was written by Michael Gladstone, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC.